Chugai Pharmaceutical Co., Ltd. (TYO:4519)

Revenue

Financials in millions JPY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Domestic Oncology Revenue	-	246.50B	247.70B
Domestic Oncology Revenue Growth	-	-0.48%	-4.80%
Domestic Specialty Revenue	-	225.80B	213.40B
Domestic Specialty Revenue Growth	-	5.81%	-28.34%
Total Domestic Revenue	480.80B	472.40B	461.10B
Total Domestic Revenue Growth	1.78%	2.45%	-17.37%
Overseas Revenue	628.90B	605.40B	536.80B
Overseas Revenue Growth	3.88%	12.78%	28.88%
Product Sales	1.11T	1.08T	997.90B
Product Sales Growth	2.95%	8.01%	2.40%
Royalties and Other Operating Income	181.60B	180.10B	172.70B
Royalties and Other Operating Income Growth	0.83%	4.29%	26.15%

Data Source: Fiscal.ai Last updated: Mar 31, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 15, 2026

Data Sources Report a data error